Press release
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
– Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients -\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.\n\n\n“These data show once again that people living with HAE still face challenges in following established guidelines for treating their attacks,” said Ben Palleiko, Chief Executive Officer of KalVista. “Even short treatment delays can lead to worse clinical outcomes, and despite efficacious on-demand treatments, the fact that they need to be injected results in barriers which lead to significant underuse and resultant overuse of long-term prophylaxis. If approved, sebetralstat should enable improved compliance with these guidelines, which has the potential to help people with HAE to better control their disease with a lower overall burden of treatment.“\n\n\nThe following presentations occurred at the 2024 HAEi Regional Conference Americas:\n\n\n\nRelationship Between Time to On-demand Treatment and Quality of Life During Hereditary Angioedema Attacks: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Oral Presentation)\n\n\nTreatment delays are associated with lower QoL and poorer general health during HAE attack, emphasizing the benefits of compliance with HAE guidelines and greater awareness of the impact of delayed treatment on QoL\n\n\n\n\n\n\nCharacterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Ricardo Zwiener, Servicio de Alergia e Inmunología Clínica, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina (Poster Presentation)\n\n\nThe time to feeling in control of an HAE attack and time to feeling fully recovered were shorter for patients treating HAE attacks in","length":3080,"tagName":"div"}]